专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120316158A1 OPHTHALMIC SOLUTION FOR TREATING OCULAR INFECTION COMPRISING LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, METHOD FOR TREATING OCULAR INFECTION, LEVOFLOXACIN OR SALT THEREOF OR SOLVATE OF THE SAME, AND USE THEREOF 审中-公开
标题翻译：用于治疗包含左炔诺孕酮或其盐或其溶解物的卵巢感染的眼科解决方案，用于治疗卵巢感染的方法，利福昔康或其盐或其溶解物的方法及其用途
公开(公告)号：US20120316158A1
公开(公告)日：2012-12-13
申请号：US13580931
申请日：2010-12-16
申请人： Takashi Nagano , Koji Sakanaka , Masatsugu Nakamura , Kouichi Kawazu , Hajime Ibuki , Kayoko Sakamoto
发明人： Takashi Nagano , Koji Sakanaka , Masatsugu Nakamura , Kouichi Kawazu , Hajime Ibuki , Kayoko Sakamoto
IPC分类号： A61K31/5383 , A61P31/04 , A61P29/00 , A61P31/00 , A61P27/02
CPC分类号： A61K31/5383 , A61K9/0048
摘要： Instillation of a 1.5% (w/v) levofloxacin ophthalmic solution three times a day, which is the dosage or dose regimen of the present invention, has features to cure bacterial conjunctivitis in a shorter time than instillation of a 0.5% (w/v) ophthalmic solution three times a day, which is the conventional dosage or dose regimen, and not to increase the rate of occurrence of side effects. Curing the ocular infection in a short time leads to shortening of the duration of exposure of the ocular-infection-causing bacterium to levofloxacin. Therefore, the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention is eventually expected to suppress emergence of the resistant bacterium resulting from the long-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen. In addition, it is confirmed that the levofloxacin ophthalmic solution in the dosage or dose regimen of the present invention directly inhibits the ocular-infection-causing bacterium such as Staphylococcus aureus from becoming resistant to levofloxacin, which results from the short-term use of the levofloxacin ophthalmic solution in the conventional dosage or dose regimen.
摘要翻译：每天三次（即本发明的剂量或剂量方案）滴注1.5％（w / v）左氧氟沙星眼用溶液具有在比滴注0.5％（w / v）的时间更短的时间内治愈细菌性结膜炎的特征）眼用溶液每天三次，这是常规剂量或剂量方案，而不是增加副作用的发生率。在短时间内治疗眼部感染导致引起眼睛感染的细菌暴露于左氧氟沙星的持续时间缩短。因此，本发明的剂量或剂量方案中的左氧氟沙星眼用溶液最终预期会抑制由常规剂量或剂量方案中长期使用左氧氟沙星眼用溶液引起的耐药性细菌的出现。此外，证实本发明的剂量或剂量方案中的左氧氟沙星眼用溶液直接抑制例如金黄色葡萄球菌引起的眼睛感染的细菌变得对左氧氟沙星具有抗性，这是由于短期使用左氧氟沙星眼科溶液在常规剂量或剂量方案中。

2. 发明申请

US20070270378A1 Viscous Agent for Ophthalmic Use 审中-公开
标题翻译：粘液剂用于眼科用途
公开(公告)号：US20070270378A1
公开(公告)日：2007-11-22
申请号：US11597440
申请日：2005-05-27
申请人： Kayoko Sakamoto , Akio Kimura , Shin-Ichiro Hirai , Masatsugu Nakamura
发明人： Kayoko Sakamoto , Akio Kimura , Shin-Ichiro Hirai , Masatsugu Nakamura
IPC分类号： A61K31/717 , A61P27/02
CPC分类号： A61K9/0048
摘要： An object of the present invention is to provide an eyedrop which has a relatively low viscosity before instillation but is thickened on the eyeball surface at instillation. The eyedrop containing a viscous agent for ophthalmic use, which comprises a combination of hydroxyethylcellulose and dextran, exhibits a specific and synergistic thickening effect in the coexistence of mucin. Therefore, the eyedrop of the present invention is thickened on the eyeball surface upon contact with mucin in the precorneal tear film at instillation, whereby a desired pharmacological efficacy or refreshing feel can be sustained.
摘要翻译：本发明的目的是提供一种滴眼剂，其在滴注之前具有相对较低的粘度，而在滴眼时在眼球表面上增稠。含有用于眼科用途的粘性剂的滴眼剂包含羟乙基纤维素和葡聚糖的组合，在粘蛋白共存中表现出特异性和协同增稠作用。因此，本发明的眼药水在滴注时与前角膜泪膜中的粘蛋白接触时在眼球表面上增稠，从而可以维持期望的药理功效或清爽感。

3. 发明授权

US5840603A Method for fabrication BiCMOS integrated circuit 失效
标题翻译： BiCMOS集成电路制造方法
公开(公告)号：US5840603A
公开(公告)日：1998-11-24
申请号：US915405
申请日：1997-08-20
申请人： Kayoko Sakamoto
发明人： Kayoko Sakamoto
IPC分类号： H01L27/06 , H01L21/8249 , H01L21/8238
CPC分类号： H01L21/8249
摘要： A first photoresist layer has opening portions in a region where an n-channel MOS transistor should be formed and in a region where a collector leading region should be formed. Then, phosphorous is implanted with taking the first photoresist layer as a mask. The first photoresist layer is then removed and a second photoresist layer is formed. The second photoresist layer has opening portions in a region where an emitter region should be formed and in the region where the collector leading region should be formed. Phosphorous is implanted with taking the second photoresist layer as a mask to form an n-type selective diffusion region in a region below the region where the emitter region should be formed and in the region where the collector leading region should be formed. Then, the second photoresist layer is removed. A polycrystalline silicon layer is formed over the entire surface and arsenic is implanted therein to make it n-type. Thereafter, heat treatment is performed to form an emitter region in the region where the emitter region should be formed and an n-type diffusion layer in the region where the collector leading region should be formed.
摘要翻译：第一光致抗蚀剂层在应该形成n沟道MOS晶体管的区域中和在应该形成集电极引导区域的区域中具有开口部分。然后，以第一光致抗蚀剂层为掩模，注入磷。然后去除第一光致抗蚀剂层，并形成第二光致抗蚀剂层。第二光致抗蚀剂层在应当形成发射极区域的区域和在应该形成集电极引导区域的区域中具有开口部分。以第二光致抗蚀剂层为掩模注入磷，在形成发射极区域的区域下方的区域和形成集电极引导区域的区域内形成n型选择扩散区域。然后，去除第二光致抗蚀剂层。在整个表面上形成多晶硅层，并且将砷注入其中以使其成为n型。此后，进行热处理，以在应该形成发射区的区域中形成发射极区域，并且在应该形成集电极引导区域的区域中形成n型扩散层。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式